NGM started at Buy by Stifel

Analyst Derek Archila initiates coverage on NGM Biopharmaceuticals (NASDAQ: NGM) with a Buy

https://www.streetinsider.com/Analyst+Comments/Stifel+Starts+NGM+Biopharmaceuticals+%28NGM%29+at+Buy/15640478.html

CymaBay started at Buy by Stifel

https://www.streetinsider.com/Analyst+Comments/Stifel+Starts+CymaBay+Therapeutic+%28CBAY%29+at+Buy/15640429.html

GENFIT, Terns in $228M Deal to Develop, Commercialize Elafibranor in China Area

https://www.streetinsider.com/Corporate+News/GENFIT+%28GNFT%29%2C+Terns+Pharmaceuticals+Announce+%24228+Million+Strategic+Partnership+to+Develop+and+Commercialize+Elafibranor+in+Greater+China/15640272.html

Conatus to Explore Strategic Alternatives, Implement Restructuring

The company has engaged Oppenheimer & Co., Inc., as its financial advisor

https://www.streetinsider.com/Corporate+News/Conatus+Pharmaceuticals+%28CNAT%29+to+Explore+Strategic+Alternatives%2C+Implement+Restructuring+Plan/15640229.html

Conatus Phase 2b Clinical Trials in NASH Didn’t Meet Primary Endpoint

https://www.streetinsider.com/Corporate+News/Conatus+Pharmaceuticals+%28CNAT%29+ENCORE-LF+and+ENCORE-PH+Phase+2b+Clinical+Trials+in+NASH+Didnt+Meet+Primary+Endpoint/15640222.html

Nabriva: EMA Validates Lefamulin Marketing Authorization Application

https://www.streetinsider.com/Corporate+News/Nabriva+%28NBRV%29+Announces+EMA+Validation+of+Marketing+Authorization+Application+for+Lefamulin/15640137.html

Minerva Neurosciences (NERV): Jefferies maintains Buy, $18 target

Jefferies analyst Biren Amin:  Clean safety profile suggests better than Zolpidem and Suvorexa

https://www.streetinsider.com/Analyst+Comments/Minerva+Neurosciences+%28NERV%29%2C+Jefferies+Says+Clean+Safety+Profile+Suggests+Its+Better+Than+Zolpidem+And+Suvorexant/15640102.html